Lantheus Holdings (LNTH) Stock Overview
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LNTH from our risk checks.
LNTH Community Fair Values
Create NarrativeSee what 134 others think this stock is worth. Follow their fair value or set your own to get alerts.
Lantheus Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$80.42 |
| 52 Week High | US$108.91 |
| 52 Week Low | US$47.25 |
| Beta | -0.14 |
| 1 Month Change | 19.73% |
| 3 Month Change | 20.71% |
| 1 Year Change | -19.00% |
| 3 Year Change | 2.02% |
| 5 Year Change | 312.20% |
| Change since IPO | 1,150.70% |
Recent News & Updates
Recent updates
We Think Lantheus Holdings (NASDAQ:LNTH) Can Stay On Top Of Its Debt
Feb 02
Lantheus: Management And Competition Raise Real Concern (Rating Downgrade)
Jan 16Positive Sentiment Still Eludes Lantheus Holdings, Inc. (NASDAQ:LNTH) Following 26% Share Price Slump
Sep 05Lantheus Holdings' (NASDAQ:LNTH) Conservative Accounting Might Explain Soft Earnings
Aug 16Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?
Aug 03Returns on Capital Paint A Bright Future For Lantheus Holdings (NASDAQ:LNTH)
Jul 12Lantheus Holdings, Inc.'s (NASDAQ:LNTH) 25% Cheaper Price Remains In Tune With Earnings
May 22Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 22Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Mar 07Lantheus Holdings: Powerhouse Potential In 2025
Jan 02Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Nov 08Lantheus: PYLARIFY's Enhanced Prospects Are Welcome, But Don't Get Too Greedy Now
Oct 21
PYLARIFY's Strategic Moves Foster Growth In Oncology And Alzheimer's Markets
Expansion into the Alzheimer's diagnostic space and strategic acquisitions suggest diversification and potential for long-term growth in revenue sources.Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
Aug 12Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
May 23Lantheus Holdings: Powerful First Quarter
May 05Lantheus Holdings: Undervalued With A Good Outlook
Feb 28Shareholder Returns
| LNTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 5.4% | -5.4% | -2.3% |
| 1Y | -19.0% | -8.5% | 20.4% |
Return vs Industry: LNTH underperformed the US Medical Equipment industry which returned -7.6% over the past year.
Return vs Market: LNTH underperformed the US Market which returned 21.2% over the past year.
Price Volatility
| LNTH volatility | |
|---|---|
| LNTH Average Weekly Movement | 4.8% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LNTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LNTH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 1,193 | Mary Heino | www.lantheus.com |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart.
Lantheus Holdings, Inc. Fundamentals Summary
| LNTH fundamental statistics | |
|---|---|
| Market cap | US$5.34b |
| Earnings (TTM) | US$233.56m |
| Revenue (TTM) | US$1.54b |
Is LNTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LNTH income statement (TTM) | |
|---|---|
| Revenue | US$1.54b |
| Cost of Revenue | US$599.66m |
| Gross Profit | US$941.95m |
| Other Expenses | US$708.39m |
| Earnings | US$233.56m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.62 |
| Gross Margin | 61.10% |
| Net Profit Margin | 15.15% |
| Debt/Equity Ratio | 52.1% |
How did LNTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 05:15 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lantheus Holdings, Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Yuan Zhi | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |